WELCOME TO
KAIROS PHARMA
Therapeutics to reverse cancer drug resistance and immune suppression
WELCOME TO
KAIROS PHARMA
Therapeutics to reverse cancer drug resistance and immune suppression
About us
Kairos Pharma, a clinical-stage biopharmaceutical company developing cancer therapeutics, aims to improve established standard of care drugs.
Kairos is a Greek word meaning “the opportune moment.” Therapeutics developed at Kairos seeks to intervene at the opportune moment that a cancer patient becomes resistant to a cancer drug. ENV 105 aims to reverse their resistance to the drug and allows the drug to become effective again.
Cancer develops resistance to drugs and suppresses the immune system. Through the power of structural biology, Kairos has developed therapeutics that reverse cancer drug resistance and immune suppression.
Advancing
Immunotherapy
Kairos Pharma is developing small molecules that target central “checkpoints” of the immune response to cancer. In addition, Kairos is developing an activated T cell therapy that transforms a patient’s T cells into killer activated T cells against the stem cells that drive the patient’s cancer.
Addressing key mechanisms of cancer drug resistance and immune suppression
New technologies developed through structural biology to reverse key mechanisms of cancer drug resistance and immune suppression. Transforming the way cancer is treated.
About us
Kairos Pharma, a clinical-stage biopharmaceutical company developing cancer therapeutics, aims to improve established standard of care drugs.
Kairos is a Greek word meaning “the opportune moment.” Therapeutics developed at Kairos seeks to intervene at the opportune moment that a cancer patient becomes resistant to a cancer drug. ENV 105 aims to reverse their resistance to the drug and allows the drug to become effective again.
Cancer develops resistance to drugs and suppresses the immune system. Through the power of structural biology, Kairos has developed therapeutics that reverse cancer drug resistance and immune suppression.
Advancing Immunotherapy
Kairos Pharma is developing small molecules that target central “checkpoints” of the immune response to cancer. In addition, Kairos is developing an activated T cell therapy that transforms a patient’s T cells into killer activated T cells against the stem cells that drive the patient’s cancer.
Addressing key mechanisms of cancer drug resistance and immune suppression.
New technologies developed through structural biology to reverse key mechanisms of cancer drug resistance and immune suppression. Transforming the way cancer is treated.
